Prostate-specific AI cleared for market
The FDA has greenlit a European company’s AI software package designed to streamline workflow for radiologists reading prostate MRIs.
Netherlands-based Quantib announced the U.S. go-ahead Wednesday, remarking that this is the sixth product in its portfolio to earn an FDA nod.
The company says the prostate offering comes with tools for lifting quality in radiology reports and efficiency in related processes.
Quantib also notes that new guidelines took effect in numerous countries this year, widely standardizing prostate MRI for patients suspected of having prostate cancer.
“Triple digit growth in MRI prostate scans is the result, but there are not enough expert radiologists to report all these extra scans,” the company comments, adding that prostate cancer represents one in four of all male cancer cases.
Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.